Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
purposeBehavioral weight loss (BWL) interventions consisting of remote coaching and self-monitoring have limited effectiveness in breast cancer survivors. We conducted a single-arm phase II study evaluating the addition of Contrave for <5% weight loss (%WL) after 2 months of BWL. PATIENTS AND
methodsWomen with prior stage 0 to III breast cancer and a body mass index ≥27 kg/m2 were eligible and initiated BWL. We collected weight, patient-reported outcomes, and labs at baseline, 2 months, and 6 months. At 2 months, participants with ≥5% WL (FAST-BWL) continued BWL, whereas those with <5% WL (SLOW-BWL) received BWL + Contrave. The primary endpoint was the proportion of SLOW-BWL with ≥5% WL at 6 months, with 30 participants providing 80% power with 5% type I error. Paired t tests, Kruskal-Wallis tests, and mixed-effects models were utilized.
resultsOf 55 participants, 2 withdrew prior to 2 months. At 2 months, 15 (28.3%) were FAST-BWL with mean% WL [standard deviation (SD)] of 7.2% (1.5) and 38 (71.7%) were SLOW-BWL with mean% WL (SD) of 1.2% (2.2). Mean% WL between 2 and 6 months was similar in SLOW-BWL (3.8% ± 3.6) and FAST-BWL (3.6% ± 2.6). At 6 months, mean% WL (SD) was 5.1% (2.9) for SLOW-BWL and 10.8% (3.5) for FAST-BWL; 13 of 15 (86.7%) FAST-BWL and 16 of 38 (42%) SLOW-BWL had ≥5% WL. Physical function and pain improved with ≥5% WL (P = 0.03 and P = 0.02, respectively). SLOW-BWL had improved HbA1c (P = 0.003) and triglycerides (P = 0.04). Gastrointestinal symptoms were reported in 74% of SLOW-BWL. Of 6 withdrawals on Contrave, 1 was due to adverse events.
conclusionsAdding Contrave for breast cancer survivors with minimal initial benefit from BWL results in clinically meaningful WL (≥5%) in 42% following 6 months of treatment, which also improves selective cardiometabolic risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.